A trial looking at dalotuzumab and ridaforolimus for children and young people with advanced cancer (MK-8669-062)

Cancer type:

Children's cancers

Status:

Results

Phase:

Phase 1

This trial looked at dalotuzumab alone and in combination with ridaforolimus. It was for children and young people whose cancer had continued to grow despite other treatment. 

The trial was open for people to join between 2012 and 2013. The team published results in 2016. There is a link to more information in the ‘Summary of results’ section below.

More about this trial

Dalotuzumab (MK-0646) is a type of immunotherapy called a monoclonal antibody.  It recognises cancer cells by looking for a specific protein on them. 

Ridaforolimus (MK-8669) is a type of targeted cancer treatment called a cancer growth blocker. It stops the signals that cancer cells use to divide and grow.

This trial was for children and young people up to 17 years old. They had a number of different cancers, including cancer of the:

The trial had 3 parts.

Part 1 looked at dalotuzumab alone. People in this part had different doses of dalotuzumab. This was so the team could find the best dose to use.

Parts 2 and 3 were due to look at the combination of dalotuzumab and ridaforolimus. But they were not completed.

The main aims of this trial were to find out:

  • the best dose of dalotuzumab and ridaforolimus to use
  • what happens to these drugs in the body
  • more about the side effects

Summary of results

We aim to add a lay summary of results to all the trials on our database. Unfortunately we have not been able to include a summary for this one.

There is more information about the results in the link below.

Phase 1 study of dalotuzumab monotherapy and ridaforolimus - dalotuzumab combination therapy in paediatric patients with advanced solid tumours
Didier Frappaz and others
European Journal of Cancer, 2016. Volume 62, pages 9-17.

Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Andrew Pearson

Supported by

Experimental Cancer Medicine Centre (ECMC)
Merck, Sharp & Dohme
NIHR Clinical Research Network: Cancer

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 9152

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think